Legend Biotech
LEGN | NASDAQ
$15.99
-$1.51 (-8.63%)
At close: Nov 16, 2026, 4:00 PM ET
$16.10
+$0.11 (+0.69%)
After-hours:
Nov 16, 2026, 7:52 PM ET
Legend Biotech Company Profile
Company profile explainedCompany Profile
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Ingrid Zhang | Chief Executive Officer |
| Carlos Santos | Chief Financial Officer |
| Alan Bash | President of CARVYKTI Business Unit |
| Ananda Elizabeth Martin | Global Compliance Officer |
| Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply |
| Joanne Choi | Senior Manager of Investor Relations |
| Robert Staloff | General Counsel |
| Surabhi Verma | Manager of Investor Relations & Corporate Communications |
| Ying Huang | Advisor |
| Yuhong Qiu | Interim Head of Research & Development and Senior VP of Regulatory Affairs |
Legend Biotech
| Country | United States |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,200 |
| CEO | Alan S. Bash |
Contact Details
2101 Cottontail Lane Somerset,
New Jersey 08873 United States
Stock Details
| Ticker Symbol | LEGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001801198 |
| CUSIP Number | 52490G102 |
| ISIN Number | US52490G1022 |
| SIC Code | 2834 |
Recent News
- 6 days ago / seekingalpha.comLegend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
- 6 days ago / marketbeat.comWhat Legend Biotech (LEGN) Said on Its Q3 Earnings Call
- 6 days ago / globenewswire.comLegend Biotech Reports Third Quarter 2026 Results and Recent Highlights
- 19 days ago / zacks.comLegend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
- 21 days ago / zacks.comLegend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
- 21 days ago / globenewswire.comLegend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
- 26 days ago / seekingalpha.comLegend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
- 2 months ago / globenewswire.comLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
- 2 months ago / globenewswire.comLegend Biotech Appoints Ingrid Zhang as Chief Executive Officer
- 2 months ago / globenewswire.comLegend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Add to Watchlist
Select watchlists to add or remove LEGN